Histamine‐ or vascular endothelial growth factor‐induced tissue factor expression and gap formation between vascular endothelial cells are synergistically enhanced by lipopolysaccharide, tumor necrosis factor‐α, interleukin (IL)‐33 or IL‐1β

The pathogenesis of chronic spontaneous urticaria (CSU), also called chronic idiopathic urticaria, has been considered to be associated with the activation of the extrinsic blood coagulation cascade. However, the trigger for the extrinsic coagulation cascade in patients with CSU remains unclear. We previously reported that histamine and lipopolysaccharide (LPS) synergistically induced the expression of tissue factor (TF), a trigger for the extrinsic coagulation cascade, in human umbilical vein endothelial cells (HUVEC). Because the elevation of tumor necrosis factor (TNF)‐α, interleukin (IL)‐33, IL‐1β and vascular endothelial growth factor (VEGF) in serum has also been observed in patients with CSU, we examined the effects of LPS, TNF‐α, IL‐33, IL‐1β, VEGF and histamine on TF expression in HUVEC by reverse transcription polymerase chain reaction and flow cytometry, as well as examining the activity that triggers the extrinsic coagulation cascade and induces intercellular gap formation of HUVEC in the presence of plasma by Actochrome® TF activity assay and impedance sensor, respectively. The expression of TF mRNA and surface protein of TF on HUVEC in response to histamine or VEGF were synergistically enhanced by the treatment with LPS, TNF‐α, IL‐33 or IL‐1β. Moreover, the activation of the extrinsic coagulation pathway and intercellular gap formation of HUVEC in response to histamine or VEGF were also synergistically increased in the presence of TNF‐α and LPS. Thus, TF expression on vascular endothelial cells was strongly enhanced by co‐stimulation with CSU‐related molecules in blood. Blocking a common pathway of LPS, TNF‐α, IL‐33 and IL‐1β, and/or that of VEGF and histamine may be an effective therapeutic measure for patients with severe and refractory CSU.

[1]  R. Cardona,et al.  Clinical Characterization of Patients with Chronic Spontaneous Urticaria according to Anti-TPO IgE Levels , 2019, Journal of immunology research.

[2]  J. S. Lee,et al.  Systematic review and meta‐analysis: Effect of Helicobacter pylori eradication on chronic spontaneous urticaria , 2019, Helicobacter.

[3]  T. Kawakami,et al.  Histamine-Releasing Factor, a New Therapeutic Target in Allergic Diseases , 2019, Cells.

[4]  Y. Yanase,et al.  Increase of tissue factor expression on the surface of peripheral monocytes of patients with chronic spontaneous urticaria , 2019, Allergy.

[5]  Y. Matsuo,et al.  Activation of Human Peripheral Basophils in Response to High IgE Antibody Concentrations without Antigens , 2018, International journal of molecular sciences.

[6]  C. Bachert,et al.  In chronic spontaneous urticaria, IgE against staphylococcal enterotoxins is common and functional , 2018, Allergy.

[7]  M. Maurer,et al.  C‐reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria , 2018, Allergy.

[8]  O. Schmetzer,et al.  IL‐24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria , 2017, The Journal of allergy and clinical immunology.

[9]  Y. Yanase,et al.  Histamine and Toll-like receptor ligands synergistically induce endothelial cell gap formation by the extrinsic coagulating pathway. , 2017, The Journal of allergy and clinical immunology.

[10]  Qiongyan Zhou,et al.  Increased plasma IL-17, IL-31, and IL-33 levels in chronic spontaneous urticaria , 2017, Scientific Reports.

[11]  M. Maurer,et al.  Potential blood biomarkers in chronic spontaneous urticaria , 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  B. Hinz,et al.  Inhibition of interleukin-1β-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2 , 2016, Oncotarget.

[13]  K. Huber,et al.  Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation , 2016, Scientific Reports.

[14]  A. Marzano,et al.  Detection of Low-Molecular-Weight Mast Cell-Activating Factors in Serum From Patients With Chronic Spontaneous Urticaria. , 2016, Journal of investigational allergology & clinical immunology.

[15]  H. Kurzen,et al.  Chronic spontaneous urticaria – a management pathway for patients with chronic spontaneous urticaria , 2015, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[16]  M. Maurer,et al.  Substance P is upregulated in the serum of patients with chronic spontaneous urticaria. , 2014, The Journal of investigative dermatology.

[17]  G. Nilsson,et al.  Molecular targets on mast cells and basophils for novel therapies. , 2014, The Journal of allergy and clinical immunology.

[18]  R. de Caterina,et al.  Involvement of the TP receptor in TNF-α-induced endothelial tissue factor expression. , 2014, Vascular pharmacology.

[19]  R. Asero,et al.  Chronic urticaria and coagulation: pathophysiological and clinical aspects , 2014, Allergy.

[20]  M. Atwa,et al.  Serum concentration of IL‐17, IL‐23 and TNF‐α among patients with chronic spontaneous urticaria: association with disease activity and autologous serum skin test , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  Y. Okayama,et al.  Significantly High Levels of Anti-dsDNA Immunoglobulin E in Sera and the Ability of dsDNA to Induce the Degranulation of Basophils from Chronic Urticaria Patients , 2013, International Archives of Allergy and Immunology.

[22]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[23]  A. Kasperska‐Zając,et al.  Plasma IL‐6 concentration correlates with clinical disease activity and serum C‐reactive protein concentration in chronic urticaria patients , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  C. Pucillo,et al.  Mast cells are critically involved in serum‐mediated vascular leakage in chronic urticaria beyond high‐affinity IgE receptor stimulation , 2011, Allergy.

[25]  M. Shima,et al.  Increase of coagulation potential in chronic spontaneous urticaria , 2011, Allergy.

[26]  Y. Kameyoshi,et al.  Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria , 2010, Allergy.

[27]  A. Marzano,et al.  Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications , 2010, Internal and emergency medicine.

[28]  R. Asero,et al.  Heparin and Tranexamic Acid Therapy May Be Effective in Treatment-Resistant Chronic Urticaria with Elevated D-Dimer: A Pilot Study , 2010, International Archives of Allergy and Immunology.

[29]  G. Nilsson,et al.  Increased mast cell expression of PAR‐2 in skin inflammatory diseases and release of IL‐8 upon PAR‐2 activation , 2010, Experimental dermatology.

[30]  A. Kaplan,et al.  Pathogenesis of chronic urticaria , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[31]  D. Fanoni,et al.  Expression of Tissue Factor by Eosinophils in Patients with Chronic Urticaria , 2008, International Archives of Allergy and Immunology.

[32]  B. Engelmann,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use only. , 2006 .

[33]  M. Lipnik-Štangelj Multiple role of histamine H1-receptor-PKC-MAPK signalling pathway in histamine-stimulated nerve growth factor synthesis and secretion. , 2006, Biochemical pharmacology.

[34]  R. Asero,et al.  Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. , 2006, The Journal of allergy and clinical immunology.

[35]  T. Luger,et al.  Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. , 2006, The Journal of investigative dermatology.

[36]  E. Millo,et al.  In chronic idiopathic urticaria autoantibodies against FcɛRII/CD23 induce histamine release via eosinophil activation , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[37]  A. Akhmedov,et al.  Histamine Induces Tissue Factor Expression Implications for Acute Coronary Syndromes , 2005, Circulation.

[38]  S. Gibbs,et al.  Chronic urticaria responding to subcutaneous heparin sodium , 2005, The British journal of dermatology.

[39]  Hua Xie,et al.  Activation of human tonsil and skin mast cells by agonists of proteinase activated receptor‐2 , 2005, Acta Pharmacologica Sinica.

[40]  B. Wedi,et al.  Chronic urticaria and infections , 2004, Current opinion in allergy and clinical immunology.

[41]  T. Zuberbier,et al.  Assessment of histamine‐releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[42]  H. Vliagoftis Thrombin Induces Mast Cell Adhesion to Fibronectin: Evidence for Involvement of Protease-Activated Receptor-11 , 2002, The Journal of Immunology.

[43]  S. Akira,et al.  Toll-like receptors; their physiological role and signal transduction system. , 2001, International immunopharmacology.

[44]  R. Parslew,et al.  Warfarin treatment of chronic idiopathic urticaria and angio‐oedema , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[45]  J. Jesty,et al.  Vascular endothelial groth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatininase a activation and cell proliferation , 1998 .

[46]  L. Petersen,et al.  Histamine is released in the wheal but not the flare following challenge of human skin in vivo: a microdialysis study , 1997, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[47]  R. Winkelmann,et al.  Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. , 1996, The Journal of investigative dermatology.

[48]  J. Kochan,et al.  Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. , 1993, The New England journal of medicine.

[49]  J. J. MEYER-DE SCHMID,et al.  [Treatment of chronic urticaria with heparin]. , 1952, Bulletin de la Societe francaise de dermatologie et de syphiligraphie.